Shares of AstraZeneca PLC (AZN) are gaining about 4 percent on Friday morning trading after the company announced positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease.
The company's shares are currently trading at $191.72 on the New York Stock Exchange, up 4.57 percent. The stock opened at $190.88 and has climbed as high as $192.97 so far in today's session. Over the past year, it has traded in a range of $122.48 to $212.71.
Tozorakimab was generally well tolerated and showed a favorable safety profile. Importantly, the treatment met its primary endpoint in both the OBERON and TITANIA Phase III trials, reinforcing its potential as a new therapeutic option for patients with COPD.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.